Formation of self-assembled triple-layered rotavirus-like particles (tlRLPs) by constitutive co-expression of VP2, VP6, and VP7 in stably transfected high-five insect cell lines

Journal of Medical Virology

Volumn 87, Issue 1, 2015, Pages 102-111

  Shoja, Zabihollah ^a,b   Tagliamonte, Maria ^c   Jalilvand, Somayeh ^b   Mollaei Kandelous, Yaghoub ^b   De stradis, Angelo ^d   Tornesello, Maria Lina ^c   Buonaguro, Franco M ^c   Buonaguro, Luigi ^c  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d Institute of Plant Virology   (Italy)

Author keywords

Antigenicity; High five insect cells; Rotavirus VP2, VP6, and VP7; TlRLP

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; RECOMBINANT PROTEIN; VIRUS PROTEIN; CAPSID PROTEIN; ROTAVIRUS VACCINE; VIROSOME; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS LIKE PARTICLE VACCINE; VP2 PROTEIN, ROTAVIRUS; VP6 PROTEIN, ROTAVIRUS; VP7 PROTEIN, ROTAVIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; INSECT CELL; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; ROTAVIRUS; TRANSMISSION ELECTRON MICROSCOPY; VIRUS LIKE AGENT; VIRUS PARTICLE; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELL LINE; GENE EXPRESSION; GENETICS; IMMUNOLOGY; INSECT; ISOLATION AND PURIFICATION; METABOLISM; PROTEIN MULTIMERIZATION; ULTRASTRUCTURE;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CAPSID PROTEINS; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; INSECTS; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, TRANSMISSION; PROTEIN MULTIMERIZATION; RECOMBINANT PROTEINS; ROTAVIRUS VACCINES; VACCINES, VIRUS-LIKE PARTICLE; VIROSOMES;

EID: 84909594718     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23973     Document Type: Article

References (67)

1. Agnello D, Herve CA, Lavaux A, Darniot M, Guillon P, Charpilienne A, Pothier P. 2006. Intrarectal immunization with rotavirus 2/6 virus-like particles induces an antirotavirus immune response localized in the intestinal mucosa and protects against rotavirus infection in mice. J Virol 80:3823-3832.
2. Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, Binka FN, Steele AD, Laserson KF, Ansah NA, Levine MM, Lewis K, Coia ML, ttah-Poku M, Ojwando J, Rivers SB, Victor JC, Nyambane G, Hodgson A, Schodel F, Ciarlet M, Neuzil KM. 2010. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: A randomised, double-blind, placebo-controlled trial. Lancet 376:606-614.
3. Barnes LM, Bentley CM, Dickson AJ. 2003. Stability of protein production from recombinant mammalian cells. Biotechnol Bioeng 81:631-639.
4. Bernard AR, Kost TA, Overton L, Cavegn C, Young J, Bertrand M, Yahia-Cherif Z, Chabert C, Mills A. 1994. Recombinant protein expression in a Drosophila cell line: Comparison with the baculovirus system. Cytotechnology 15:139-144.
5. Bernstein DI, Sack DA, Rothstein E, Reisinger K, Smith VE, O'Sullivan D, Spriggs DR, Ward RL. 1999. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: A randomised placebo-controlled trial. Lancet 354:287-290.
6. Bertolotti-Ciarlet A, Ciarlet M, Crawford SE, Conner ME, Estes MK. 2003. Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice. Vaccine 21:3885-3900.
7. Bishop RF, Davidson GP, Holmes IH, Ruck BJ. 1973. Virus particles in epithelial cells of duodenal mucosa from children with acute non-bacterial gastroenteritis. Lancet 2:1281-1283.
8. Bishop RF, Davidson GP, Holmes IH, Ruck BJ. 1974. Detection of a new virus by electron microscopy of faecal extracts from children with acute gastroenteritis. Lancet 1:149-151.
9. Buonaguro L, Buonaguro FM, Tornesello ML, Mantas D, Beth-Giraldo E, Wagner R, Michelson S, Prevost MC, Wolf H, Giraldo G. 2001. High efficient production of Pr55(gag) virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. Antiviral Res 49:35-47.
10. Chackerian B. 2007. Virus-like particles: Flexible platforms for vaccine development. Expert Rev Vaccines 6:381-390.
11. Charpilienne A, Nejmeddine M, Berois M, Parez N, Neumann E, Hewat E, Trugnan G, Cohen J. 2001. Individual rotavirus-like particles containing 120 molecules of fluorescent protein are visible in living cells. J Biol Chem 276:29361-29367.
12. Conner ME, Crawford SE, Barone C, O'Neal C, Zhou YJ, Fernandez F, Parwani A, Saif LJ, Cohen J, Estes MK. 1996. Rotavirus subunit vaccines. Arch Virol Suppl 12:199-206.
13. Crawford SE, Labbe M, Cohen J, Burroughs MH, Zhou YJ, Estes MK. 1994. Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells. J Virol 68:5945-5952.
14. Crawford SE, Estes MK, Ciarlet M, Barone C, O'Neal CM, Cohen J, Conner ME. 1999. Heterotypic protection and induction of a broad heterotypic neutralization response by rotavirus-like particles. J Virol 73:4813-4822.
15. Douris V, Swevers L, Labropoulou V, Andronopoulou E, Georgoussi Z, Iatrou K. 2006. Stably transformed insect cell lines: Tools for expression of secreted and membrane-anchored proteins and high-throughput screening platforms for drug and insecticide discovery. Adv Virus Res 68:113-156.
16. Estes MK, Kapikian AZ. 2007. Rotavirus. In: Fields virology. 5th edition. Knipe DM, Howley PN, editors. Philadelphia, PA: Lippincott Williams & Wilkins. pp 1917-1974.
17. Fromantin C, Jamot B, Cohen J, Piroth L, Pothier P, Kohli E. 2001. Rotavirus 2/6 virus-like particles administered intranasally in mice, with or without the mucosal adjuvants cholera toxin and Escherichia coli heat-labile toxin, induce a Th1/Th2-like immune response. J Virol 75:11010-11016.
18. Gonzalez SA, Affranchino JL. 1995. Assembly of double-layered virus-like particles in mammalian cells by coexpression of human rotavirus VP2 and VP6. J Gen Virol 76:2357-2360.
19. Grgacic EV, Anderson DA. 2006. Virus-like particles: Passport to immune recognition. Methods 40:60-65.
20. Istrate C, Hinkula J, Charpilienne A, Poncet D, Cohen J, Svensson L, Johansen K. 2008. Parenteral administration of RF 8-2/6/7 rotavirus-like particles in a one-dose regimen induce protective immunity in mice. Vaccine 26:4594-4601.
21. Jennings GT, Bachmann MF. 2008. The coming of age of virus-like particle vaccines. Biol Chem 389:521-536.
22. Jiang B, Barniak V, Smith RP, Sharma R, Corsaro B, Hu B, Madore HP. 1998. Synthesis of rotavirus-like particles in insect cells: Comparative and quantitative analysis. Biotechnol Bioeng 60:369-374.
23. Jiang B, Gentsch JR, Glass RI. 2008. Inactivated rotavirus vaccines: A priority for accelerated vaccine development. Vaccine 26:6754-6758.
24. Johansen K, Schroder U, Svensson L. 2003. Immunogenicity and protective efficacy of a formalin-inactivated rotavirus vaccine combined with lipid adjuvants. Vaccine 21:368-375.
25. Johnson JE, Chiu W. 2000. Structures of virus and virus-like particles. Curr Opin Struct Biol 10:229-235.
26. Kapikian AZ, Kim HW, Wyatt RG, Rodriguez WJ, Ross S, Cline WL, Parrott RH, Chanock RM. 1974. Reoviruslike agent in stools: Association with infantile diarrhea and development of serologic tests. Science 185:1049-1053.
27. Kim Y, Chang KO, Kim WY, Saif LJ. 2002. Production of hybrid double- or triple-layered virus-like particles of group A and C rotaviruses using a baculovirus expression system. Virology 302:1-8.
28. Kollewe C, Vilcinskas A. 2013. Production of recombinant proteins in insect cells. Am J Biochem Biotechnol 9:255-271.
29. Labbe M, Charpilienne A, Crawford SE, Estes MK, Cohen J. 1991. Expression of rotavirus VP2 produces empty corelike particles. J Virol 65:2946-2952.
30. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
31. Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, Ngwira B, Victor JC, Gillard PH, Cheuvart BB, Han HH, Neuzil KM. 2010. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 362:289-298.
32. McCarroll L, King LA. 1997. Stable insect cell cultures for recombinant protein production. Curr Opin Biotechnol 8:590-594.
33. McNeal MM, Rae MN, Conner ME, Ward RL. 1998. Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21. Virology 243:158-166.
34. McNeal MM, Rae MN, Ward RL. 1999. Effects of different adjuvants on rotavirus antibody responses and protection in mice following intramuscular immunization with inactivated rotavirus. Vaccine 17:1573-1580.
35. Mellado MC, Mena JA, Lopes A, Ramirez OT, Carrondo MJ, Palomares LA, Alves PM. 2009. Impact of physicochemical parameters on in vitro assembly and disassembly kinetics of recombinant triple-layered rotavirus-like particles. Biotechnol Bioeng 104:674-686.
36. Mena JA, Ramirez OT, Palomares LA. 2006. Intracellular distribution of rotavirus structural proteins and virus-like particles expressed in the insect cell-baculovirus system. J Biotechnol 122:443-452.
37. Milne RG. 1993. Electron microscopy of in vitro preparations. In: Diagnosis of plant virus diseases. Matthews REF, editor. Boca Raton, FL: CRC Press, pp 215-251.
38. Mirzaei M, Xu Y, Elias CB, Prakash S. 2009. Nonviral production of human interleukin-7 in spodoptera frugiperda insect cells as a soluble recombinant protein. J Biomed Biotechnol 2009:637942.
39. Molinari P, Peralta A, Taboga O. 2008. Production of rotavirus-like particles in Spodoptera frugiperda larvae. J Virol Methods 147:364-367.
40. Murphy TV, Gargiullo PM, Massoudi MS, Nelson DB, Jumaan AO, Okoro CA, Zanardi LR, Setia S, Fair E, LeBaron CW, Wharton M, Livengood JR. 2001. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 344:564-572.
41. Murphy BR, Morens DM, Simonsen L, Chanock RM, La M, Jr., Kapikian AZ. 2003. Reappraisal of the association of intussusception with the licensed live rotavirus vaccine challenges initial conclusions. J Infect Dis 187:1301-1308.
42. Noad R, Roy P. 2003. Virus-like particles as immunogens. Trends Microbiol 11:438-444.
43. O'Neal CM, Crawford SE, Estes MK, Conner ME. 1997. Rotavirus virus-like particles administered mucosally induce protective immunity. J Virol 71:8707-8717.
44. O'Neal CM, Clements JD, Estes MK, Conner ME. 1998. Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge. J Virol 72:3390-3393.
45. Palomares LA, Lopez S, Ramirez OT. 2002. Strategies for manipulating the relative concentration of recombinant rotavirus structural proteins during simultaneous production by insect cells. Biotechnol Bioeng 78:635-644.
46. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. 2003. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 9:565-572.
47. Parashar UD, Gibson CJ, Bresse JS, Glass RI. 2006. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 12:304-306.
48. Parez P. 2008. Rotavirus gastroenteritis: Why to back up the development of new vaccines? Comp Immun Microbiol Infect Dis 31:253-269.
49. Parez N, Fourgeux C, Mohamed A, Dubuquoy C, Pillot M, Dehee A, Charpilienne A, Poncet D, Schwartz-Cornil I, Garbarg-Chenon A. 2006. Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection. J Virol 80:1752-1761.
50. Pfeifer TA. 1998. Expression of heterologous proteins in stable insect cell culture. Curr Opin Biotechnol 9:518-521.
51. Rodriguez-Limas WA, Tyo KE, Nielsen J, Ramirez OT, Palomares LA. 2011. Molecular and process design for rotavirus-like particle production in Saccharomyces cerevisiae. Microb Cell Fact 10:33.
52. Roldao A, Mellado MC, Lima JC, Carrondo MJ, Alves PM, Oliveira R. 2012. On the effect of thermodynamic equilibrium on the assembly efficiency of complex multi-layered virus-like particles (VLP): The case of rotavirus VLP. PLoS Comput Biol 8:e1002367.
53. Rovinski B, Haynes JR, Cao SX, James O, Sia C, Zolla-Pazner S, Matthews TJ, Klein MH. 1992. Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: Implications for development of a cross-protective AIDS vaccine. J Virol 66:4003-4012.
54. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, Cervantes Y, Linhares AC, Lopez P, ias-Parra M, Ortega-Barria E, Richardson V, Rivera-Medina DM, Rivera L, Salinas B, Pavia-Ruz N, Salmeron J, Ruttimann R, Tinoco JC, Rubio P, Nunez E, Guerrero ML, Yarzabal JP, Damaso S, Tornieporth N, Saez-Llorens X, Vergara RF, Vesikari T, Bouckenooghe A, Clemens R, De VB, O'Ryan M. 2006. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 354:11-22.
55. Schirmbeck R, Bohm W, Reimann J. 1996. Virus-like particles induce MHC class I-restricted T-cell responses. Lessons learned from the hepatitis B small surface antigen. Intervirology 39:111-119.
56. Shoja Z, Tagliamonte M, Jalilvand S, Ziaee AA, Mokhtari-Azad T, Hamkar R, Shahmahmoodi S, Rezaei F, Tornesello M, Buonaguro FM, Nategh R, Buonaguro L. 2012. Molecular characterization analysis of the outer protein layer (VP7) from human rotavirus A genotype G1 isolate identified in Iran: Implications for vaccine development. New Microbiol 35:415-427.
57. Shoja Z, Tagliamonte M, Jalilvand S, Mokhtari-Azad T, Hamkar R, Shahmahmoodi S, Rezaei F, Tornesello M, Buonaguro FM, Buonaguro L, Nategh R. 2013. Development of a stable insect cell line constitutively expressing rotavirus VP2. Virus Res 172:66-74.
58. Shuttleworth G, Eckery DC, Awram P. 2005. Oral and intraperitoneal immunization with rotavirus 2/6 virus-like particles stimulates a systemic and mucosal immune response in mice. Arch Virol 150:341-349.
59. Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD. 2011. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: A systematic review and meta-analysis. Lancet Infect Dis 12:136-141.
60. Tosser G, Labbe M, Bremont M, Cohen J. 1992. Expression of the major capsid protein VP6 of group C rotavirus and synthesis of chimeric single-shelled particles by using recombinant baculoviruses. J Virol 66:5825-5831.
61. Vesikari T, Clark HF, Offit PA, Dallas MJ, DiStefano DJ, Goveia MG, Ward RL, Schodel F, Karvonen A, Drummond JE, DiNubile MJ, Heaton PM. 2006a. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine 24:4821-4829.
62. Vesikari T, Matson DO, Dennehy P, Van DP, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, Shinefield HR, Christie CD, Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gothefors L, Campens D, Karvonen A, Watt JP, O'Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit PA, Heaton PM. 2006b. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 354:23-33.
63. Vieira HL, Estevao C, Roldao A, Peixoto CC, Sousa MF, Cruz PE, Carrondo MJ, Alves PM. 2005. Triple layered rotavirus VLP production: Kinetics of vector replication, mRNA stability and recombinant protein production. J Biotechnol 120:72-82.
64. YanMei Y, Xia LI, Hui Y, Yuan Q, You Z, RongXiang F, XiaoYing C. 2011. Immunogenicity and virus-like particle formation of rotavirus capsid proteins produced in transgenic plants. Sci China Life Sci 54:82-89.
65. Zaman K, Dang DA, Victor JC, Shin S, Yunus M, Dallas MJ, Podder G, Vu DT, Le TP, Luby SP, Le HT, Coia ML, Lewis K, Rivers SB, Sack DA, Schodel F, Steele AD, Neuzil KM, Ciarlet M. 2010. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: A randomised, double-blind, placebo-controlled trial. Lancet 376:615-623.
66. Zeng CQ, Labbe M, Cohen J, Prasad BV, Chen D, Ramig RF, Estes MK. 1994. Characterization of rotavirus VP2 particles. Virology 201:55-65.
67. Zeng CQ, Wentz MJ, Cohen J, Estes MK, Ramig RF. 1996. Characterization and replicase activity of double-layered and single-layered rotavirus-like particles expressed from baculovirus recombinants. J Virol 70:2736-2742.